Supernus Pharmaceuticals
SUPN
#5037
Rank
NZ$3.16 B
Marketcap
NZ$54.33
Share price
1.78%
Change (1 day)
-33.52%
Change (1 year)

Earnings for Supernus Pharmaceuticals (SUPN)

Earnings in 2026 (TTM): -NZ$63.39 Million

According to Supernus Pharmaceuticals 's latest financial reports the company's current earnings are NZ$0.86 Billion. In 2025 the company made an earning of -NZ$77.19 Million a decrease over its 2024 earnings that were of NZ$0.14 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Supernus Pharmaceuticals from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -NZ$63.39 Million-17.88%
2025 -NZ$77.19 Million-152.66%
2024 NZ$0.14 B1446.62%
2023 NZ$9.47 M-92.36%
2022 NZ$0.12 B-29.8%
2021 NZ$0.17 B-49.79%
2020 NZ$0.35 B12.99%
2019 NZ$0.31 B7.58%
2018 NZ$0.28 B54.9%
2017 NZ$0.18 B84.25%
2016 NZ$0.10 B202.27%
2015 NZ$33.54 M-462.04%
2014 -NZ$9.27 Million-94%
2013 -NZ$0.16 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Johnson & Johnson
JNJ
NZ$34.22 B-51,828.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
NZ$13.19 B-20,044.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$63.55 B-96,171.40%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$20.71 B-31,411.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Zogenix
ZGNX
-NZ$0.39 Billion 485.87%๐Ÿ‡บ๐Ÿ‡ธ USA
United Therapeutics
UTHR
NZ$2.77 B-4,299.11%๐Ÿ‡บ๐Ÿ‡ธ USA